Brown University

New FDA-Approved procedure preserves blood flow while repairing life-threatening aneurysms This device expands treatment options for patients who previously might not have been candidates for minimally invasive repair” — Dr. Jeffery Slaiby, Vascular Surgeon at Brown Surgical Associates PROVIDENCE, RI, UNITED STATES, September 4, 2025 / EINPresswire.com / -- Brown Surgical Associates is proud to announce that Dr. Jeffery Slaiby and Dr. Peter Soden recently became the first surgeons in New England to implant the newly FDA-approved Zenith ® Iliac Branch Device (ZBIS) . The procedure took place on July 29, 2025, at Rhode Island Hospital , marking a major step forward in treating patients with aortoiliac and iliac aneurysms. The device, which gained FDA approval in May of this year, is built on Cook Medical’s proven Zenith platform and is designed to offer a safer, minimally invasive option for patients with these life-threatening conditions. The ZBIS graft not only repairs aneurysms but also preserves blood flow to the internal iliac artery—helping reduce risks like pain, sexual dysfunction, and other complications. “This device expands treatment options for patients who previously might not have been candidates for minimally invasive repair,” said Dr. Slaiby. “It’s exciting to bring this technology to Rhode Island and be the first in New England to perform this life-changing surgery.” Dr. Soden added, “The ability to treat aneurysms while preserving blood flow is a significant advancement. We’re proud to offer our patients the latest in innovative vascular care right here at Rhode Island Hospital.” Clinical trial data show strong long-term outcomes, including durable aneurysm repair and 97% of patients free from buttock claudication at five years. Cook Medical has called the launch of ZBIS an important addition to its aortic device portfolio, expanding treatment options and improving patient results. About Brown Surgical Associates Brown Surgical Associates is Rhode Island's largest multidisciplinary surgical group and a founding member of Brown Physicians, Inc. Our more than 50 surgeons are recognized for their experience in highly specialized areas of surgery. We offer the latest surgical techniques, such as minimally invasive and robotic-assisted surgery, and many of our physicians also participate in groundbreaking research and clinical trials. Our doctors are not only surgeons, they are educators. All of them are on the teaching staff at the Warren Alpert Medical School of Brown University, training the next generation of surgeons. Each of our surgeons is board-certified or board-eligible by the American Board of Surgery. Along with expert care, we strive to provide the best patient experience possible. That means 13 offices, located conveniently throughout Rhode Island and southern Massachusetts, and surgeons who can operate at eight hospitals across the area. Peter Lucas Practice Marketing & Communications +1 401-525-8113 pete@practicemarcomm.com Visit us on social media: LinkedIn Bluesky Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Public Domain The new additions would bring ACIP membership to 14 total. Several of the proposed members have taken part in anti-vaccine activity or made anti-vaccine statements. Health Secretary Robert F. Kennedy Jr. is planning to add seven new members to the CDC’s Advisory Committee for Immunization Practices, multiple outlets reported Thursday morning. The new additions would bring ACIP’s total membership to 14 voting members. The news comes three months after Kennedy unilaterally fired all 17 members of the committee and appointed eight new members, one of whom later resigned, and as the head of Health and Human Services (HHS) today faces the Senate Finance Committee for an already heated discussion. The proposed new ACIP members, as first reported by Inside Medicine , are: Hillary Blackburn, a pharmacist and director of pharmaceutical services at Dispensary of Hope, a pharmaceutical charity. Joseph Fraiman, an emergency medicine physician based in New Orleans. John Gaitanis, a pediatric neurologist at Brown University in Rhode Island. Evelyn Griffin, an obstetrician based in Louisiana. Kirk Milhoan, a pediatric cardiologist and pastor in Hawai’i. Raymond Pollak, the former chief of transplant surgery at the University of Illinois. Catherine Stein, an epidemiologist at Case Western Reserve University. None of the new members appear to have direct vaccine or infectious disease experience. Like other additions that Kennedy has made to ACIP, several of the new appointees have made anti-vaccine or vaccine-critical remarks. Fraiman is the author of a 2022 paper that called into question the safety of mRNA vaccines. He also wrote the Hope Accord, a public petition calling for the withdrawal of mRNA vaccines. Milhoan is affiliated with the Independent Medical Alliance, a group critical of COVID-19 vaccines. Gaitanis, according to reports from a variety of outlets, has appeared as an expert witness in multiple lawsuits alleging injury from vaccines. When Kennedy replaced the entirety of ACIP in June, he quickly added a slate of new members, several of whom had made anti-vaccine comments and were involved in anti-vaccine groups. Robert Malone and Martin Kulldorff , two of the current members, have both appeared as witnesses in lawsuits against vaccine manufacturer Merck. Malone, who is also affiliated with Medical Alliance, has testified in front of Congress that mRNA vaccines can cause cancer and autoimmune disease, without evidence. Kennedy is adding the new members to ACIP shortly after pushing for the firing of CDC Director Susan Monarez when she refused to sign off on rolling back certain COVID-19 vaccine approvals.

Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatment optionsLONDON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- TREOS Bio Ltd., a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, today announced the execution of clinical collaboration agreements with Charité – Universitätsmedizin Berlin and Junshi Biosciences for the initiation of OBERTO-202, a potentially registration-enabling Phase II clinical trial evaluating PolyPEPI1018 in combination with toripalimab (Junshi Biosciences' PD-1 inhibitor) and standard of care in microsatellite stable (MSS) metastatic colorectal cancer (CRC). The company also completed a $2.1 million bridge financing from existing investors, bringing total financing raised to date to $47M, not counting non-dilutive support from grants and clinical collaborations. The OBERTO-202 study will be conducted as an investigator-led trial at Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, with Prof. Sebastian Stintzing as principal investigator and in collaboration with 14 other leading academic hospitals. The trial will evaluate PolyPEPI1018 and toripalimab in combination with standard of care (Lonsurf + Avastin) versus standard of care alone in approximately 140 patients with relapsed/refractory MSS CRC. "The collaboration with Charité Berlin and Junshi Biosciences represents a significant milestone as we work toward demonstrating the potential of our precision immunotherapy approach in one of the largest oncology markets with significant unmet medical need," said Dr. Christopher Gallen, Chairman and CEO of TREOS Bio. "The bridge financing provides us with the runway to advance our lead program toward what we anticipate will be a registration-enabling Phase II study." “This randomized, controlled clinical trial represents a logical next step in the development of PolyPEPI1018,” said Dr. Hagop Youssoufian, Chair of Medical Strategy of TREOS Bio and Adjunct Professor of Medicine at Brown University. “Leveraging the built-in antigenic diversity of this unique active immunotherapy that can dampen multiple immunosuppressive mechanisms, in combination with toripalimab and chemotherapy, provides an exciting opportunity to overcome the well-known resistance to immunotherapies in MSS CRC.” PolyPEPI1018 is TREOS Bio's lead off-the-shelf multi-peptide active cancer immunotherapy designed to convert immunologically "cold" tumors to "hot" tumors. The therapy has demonstrated encouraging clinical activity across three Phase I/II trials (44 patients in total) in advanced MSS CRC conducted in partnership with the Mayo Clinic, with consistent correlations between immune activation and clinical benefit. MSS CRC represents approximately 85% of all colorectal cancer cases and affects an estimated 130,000 new patients annually in the US alone and over 1.6 million new patients globally. Current immunotherapies, including checkpoint inhibitors, have shown limited efficacy in this patient population. About TREOS Bio TREOS Bio is a clinical-stage biotechnology company developing precision cancer immunotherapies based on its proprietary PASCal (Personal Antigen Selection Calculator) platform. The company's lead program, PolyPEPI1018, is an off-the-shelf multi-peptide immunotherapy targeting shared tumor antigens with demonstrated clinical activity in MSS colorectal cancer. TREOS Bio has partnerships with leading institutions including Mayo Clinic, Charité – Universitätsmedizin Berlin, Roche and Junshi Biosciences. For more information, visit www.treosbio.com. Forward-Looking Statements This press release contains forward-looking statements regarding TREOS Bio's clinical development plans and anticipated timelines. Actual results may differ materially from those indicated by such forward-looking statements. Media Contact:Sidharth Mehtasmehta@allelecapital.com